Get startedLog in
    Picture of Neovacs SA logo

    ALNEV — Neovacs SA Income Statement

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Neovacs SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    FAS    		—
    FAS
    FAS
    FAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue0.030.0230.0010.5330.291
    Cost of Revenue
    Gross Profit-0.09-0.462-0.5760.029-0.033
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses4.5910.67.478.017.37
    Operating Profit-4.56-10.6-7.47-7.47-7.08
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-6.68-12.5-4.35-9.62-33.9
    Provision for Income Taxes
    Net Income After Taxes-6.14-11.8-3.55-8.74-32.9
    Net Income Before Extraordinary Items
    Net Income-6.14-11.8-3.55-8.74-32.9
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-6.14-11.8-3.55-8.74-32.9
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS——-9,602,307,833-238,146-187
    Dividends per Share